|
|
Résultats pour
brevets
1.
|
Compositions and methods for thromboembolism dissolution
| Numéro d'application |
16304769 |
| Numéro de brevet |
11065310 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2017-05-26 |
| Date de la première publication |
2020-08-13 |
| Date d'octroi |
2021-07-20 |
| Propriétaire |
NATTOCAT, LLC (USA)
|
| Inventeur(s) |
Raiszadeh, Michelle Monier
|
Abrégé
Disclosed herein are novel thrombolytic formula for safe and effective treatment of blood clots. In clinical trials, cats of various breeds and ages presented partial or full paralysis of one or more limbs, due to arterial thromboembolism (ATE). Average treatment ranged from 3 days to 2 weeks, depending on the clot size and time elapsed since clot was dislodged from the subject's heart. These are significant findings considering the lack of treatment options available in veterinary medicine for cats with HCM and ATE. Veterinarians often euthanize cats presenting ATE, as no safe and effective thrombolytic agent is currently available for veterinary use. Previous thrombolytics were shown to have an average mortality rate of 60% due to reperfusion injury and hemorrhaging. The disclosed formula, on the other hand, overcomes these shortcomings.
Classes IPC ?
- A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
- A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
- A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
- A61K 9/28 - DragéesPilules ou comprimés avec revêtements
- A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
- A61K 36/75 - Rutaceae (famille de la rue)
|
2.
|
COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION
| Numéro d'application |
US2017034759 |
| Numéro de publication |
2017/205790 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2017-05-26 |
| Date de publication |
2017-11-30 |
| Propriétaire |
NATTOCAT, LLC (USA)
|
| Inventeur(s) |
Raiszadeh, Michelle Monier
|
Abrégé
Disclosed herein are novel thrombolytic formula for safe and effective treatment of blood clots. In clinical trials, cats of various breeds and ages presented partial or full paralysis of one or more limbs, due to arterial thromboembolism (ATE). Average treatment ranged from 3 days to 2 weeks, depending on the clot size and time elapsed since clot was dislodged from the subject's heart. These are significant findings considering the lack of treatment options available in veterinary medicine for cats with HCM and ATE. Veterinarians often euthanize cats presenting ATE, as no safe and effective thrombolytic agent is currently available for veterinary use. Previous thrombolytics were shown to have an average mortality rate of 60% due to reperfusion injury and hemorrhaging. The disclosed formula, on the other hand, overcomes these shortcomings.
Classes IPC ?
- A61K 9/20 - Pilules, pastilles ou comprimés
- A61K 9/28 - DragéesPilules ou comprimés avec revêtements
- A61K 36/75 - Rutaceae (famille de la rue)
- A61K 38/43 - EnzymesProenzymesLeurs dérivés
- A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
- A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
|
|